SCHEMBL7065752

SCHEMBL7065752

Nc1ncnc2c1ncn2[C@H]1C[C@H](O)[C@@H](COC(c2ccccc2)(c2ccccc2)c2ccccc2)O1

nearest known ligand 0.71

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TYMP P19971 4/20 0.71
POLB P06746 1/20 0.59
ADORA1 P30542 2/20 0.58
ENPP1 P22413 3/20 0.58
P2RY1 P47900 1/20 0.58
NT5E P21589 1/20 0.49
HIF1A Q16665 1/20 0.48
ADORA3 P0DMS8 1/20 0.47
ADORA2A P29274 1/20 0.47
PNP P00491 1/20 0.47
LMNA P02545 1/20 0.47
TP53 P04637 1/20 0.47
HTT P42858 1/20 0.47
PDE4D Q08499 1/20 0.47
PDE3A Q14432 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7065756 1.00 TYMP (0.71) TYMPPOLBADORA1ENPP1P2RY1
SCHEMBL1774838 0.93 TYMP (0.63) TYMPPOLBADORA1ENPP1P2RY1
SCHEMBL29529385 0.93 TYMP (0.63) TYMPPOLBADORA1ENPP1P2RY1
SCHEMBL7871248 0.93 TYMP (0.63) TYMPPOLBADORA1ENPP1P2RY1
SCHEMBL1774839 0.93 TYMP (0.63) TYMPPOLBADORA1ENPP1P2RY1
SCHEMBL29574745 0.93 TYMP (0.63) TYMPPOLBADORA1ENPP1P2RY1
SCHEMBL6910499 0.87 TYMP (0.57) TYMPPOLBADORA1ENPP1P2RY1
SCHEMBL18817976 0.87 TYMP (0.58) TYMPPOLBADORA1ENPP1P2RY1
SCHEMBL10430363 0.86 TYMP (0.54) TYMPPOLBADORA1ENPP1P2RY1
SCHEMBL22367653 0.85 TYMP (0.65) TYMPPOLBENPP1P2RY1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030204079-A1 Process for producing 2', 3'-diethy substituted nucleoside derivatives AJINOMOTO CO., INC (JP) 2003-10-30 US disclosed
US-6579976-B2 Producing compounds having sugar-moiety hydroxyl groups or halogen atoms reduced in nucleic acids by allowing O-thiocarbonyl derivatives or halogenated derivatives in the sugar-moiety react with hypophosphorous acids or salts AJINOMOTO CO., INC. (JP) 2003-06-17 US disclosed
US-20020045744-A1 PROCESS FOR PRODUCING NUCLEIC ACID DERIVATIVES AJINOMOTO CO., INC. (JP) 2002-04-18 US disclosed
EP-0999218-A1 Process for producing nucleoside derivatives Ajinomoto Co., Inc. (JP) 2000-05-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030204079-A1 Process for producing 2', 3'-diethy substituted nucleoside derivatives RNGTT, DOHH, NT5C3B TYMP 38/4885POLB 183/4885ADORA1 2863/4885
US-20020045744-A1 PROCESS FOR PRODUCING NUCLEIC ACID DERIVATIVES RNGTT, OSGEP, PNP TYMP 19/4885POLB 77/4885ADORA1 2231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.